Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00741611 · ClinicalTrials.gov registry record · Phase 3
Study of HD Mesh Ablation System for Treatment of Paroxysmal Atrial Fibrillation
A Phase 3 study, sponsored by C. R. Bard.
- Terminated
- Registry status
- Phase 3
- Development phase
- 44
- Enrollment target
NCT00741611: Clinical Trial Phase 3 study, sponsored by C. R. Bard.
NCT00741611 is a Phase 3 study that was terminated before completion, run by C. R. Bard. The registered enrollment target is 44 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00741611, a Phase 3 study, was terminated before completion, sponsored by C. R. Bard.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 44 participants
- Enrollment target
Study Summary
This is a randomized controlled study of the Bard High Density Mesh Ablation System for treatment of paroxysmal atrial fibrillation. This study will determine if the HD Mesh Ablation System is as safe as and more effective than anti-arrhythmic drugs.
Primary Outcome
A Major Complication was defined as any adverse event that met the following criteria: 1) event was a Serious Adverse Event; 2) event was related to study device (mesh/mesh toolkit) or study procedure and 3)event was a) a cardiovascular adverse event occurring within 7 days of the procedure and/or b) a direct ablation effect adverse event occurring within 12 months of the study procedure.
Interventions
- DEVICE HD Mesh Ablation System
- DRUG Anti-arrhythmic drugs
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2008-07 |
| Est. Completion | 2009-11 |
| Phase | Phase 3 |
Why NCT00741611 stopped before completion
NCT00741611 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 44 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 2 interventions - of which HD Mesh Ablation System is the first listed.
NCT00741611 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00741611 about?
NCT00741611 is a clinical study titled "Study of HD Mesh Ablation System for Treatment of Paroxysmal Atrial Fibrillation". This is a randomized controlled study of the Bard High Density Mesh Ablation System for treatment of paroxysmal atrial fibrillation. This study will determine if the HD Mesh Ablation System is as safe as and more effective than anti-arrhythmic drugs.
What is the current status of trial NCT00741611?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 44 participants. The study started on 2008-07. Estimated completion is 2009-11.
What interventions are being tested in trial NCT00741611?
The interventions under investigation include: HD Mesh Ablation System (DEVICE), Anti-arrhythmic drugs (DRUG).
Who is sponsoring clinical trial NCT00741611?
This trial is sponsored by C. R. Bard, which has 75 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00741611's enrollment target sits among peer trials
44 1874th of 2000 higher than 125 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02323945 · 44 participants · NA
Effects of Breathing Mild Bouts of Low Oxygen on Limb Mobility After Spinal Injury
- NCT03093909 · 44 participants · Phase 1
Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases
- NCT03104491 · 44 participants · Phase 1
Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia
- NCT03781765 · 44 participants · Phase 4
Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia